


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Previously Presented) A peptide compound of formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,

X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ is one or more α -aminocarboxylic acid residue(s), the α -aminocarboxylic acid residue(s) having a length of 500 to 2500 pm


wherein

the amino acids mentioned are optionally derivatized,

the D and the L forms of the optically active amino acid residues are included,

a physiologically acceptable salt or a solvate thereof.

Claim 2. (Currently Amended) A peptide compound according to claim 1, of formula I



in which

X¹ is Ser, Gly or Thr,

X² is Leu, Ile, Nle, Val or Phe,

X³ is Asp, Glu, Lys or Phe,

X⁴ is Gly, Ala or Ser,

X⁵ is Leu, Ile, Nle, Val or Phe,

X⁶ is Arg, Har or Lys,

R¹ is 1-10 amino acids selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and

H₂N-(CH₂CH₂O)_m-(CH₂)_n-COOH, wherein

m,n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12,

with the proviso that m + n > 0

wherein

the amino acids mentioned are optionally derivatized,

the D and the L forms of the optically active amino acid residues are included, or a physiologically acceptable salt or a solvate thereof.

Claim 3. (Previously Presented) A peptide compound according to Claim 1 selected from the group consisting of
cyclo (Arg-Gly-Asp-Leu-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-Asp-Gly-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Ala-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Gly-Gly-Gly),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aha),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg-Aee),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg-Abu-Abu),
cyclo (Arg-Thr-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),
cyclo (Arg-Gly-Asp-Leu-D-Asp-Ala-Leu-Arg- β-Ala),
or a physiologically acceptable salt or a solvate thereof.

Claim 4. (Cancelled)

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Withdrawn) A pharmaceutical preparation comprising at least one compound according to Claim 1 and a vehicle, an excipient or an active ingredient.

Claim 8. (Withdrawn) A method for the treatment or prevention of a disorder related to the function of an $\alpha_v\beta_6$ integrin receptor, said method comprising administering a peptide compound of Claim 1.

Claim 9. (Withdrawn) A method according to claim 8 comprising administering said peptide compound for the control of thromboses, cardiac infarct, coronary heart disorders, arteriosclerosis, tumors, osteoporosis, fibrosis, inflammation, infections, psoriasis or for influencing wound healing process.

Claim 10. (Previously Presented) A compound according to claim 1, wherein R^1 has a length of 600 to 2500 pm.

Claim 11. (Previously Presented) A compound according to claim 1, wherein R^1 has a length of 600 to 2000 pm.

Claim 12. (Currently Amended) A compound according to claim 1, wherein amino acids which form R^1 are selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and $H_2N-(CH_2CH_2O)_m-(CH_2)_n-COOH$ wherein

m,n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12,

with the proviso that $m + n > 0$.

Claim 13. (Previously Presented) A compound according to claim 1, wherein X^1 is Gly or Thr.

Claim 14. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, and X² is Leu.

Claim 15. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, and X³ is Asp or D-Asp.

Claim 16. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, X³ is Asp or D-Asp, and X⁴ is Gly or Ala.

Claim 17. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, X³ is Asp or D-Asp, X⁴ is Gly or Ala, and X⁵ is Leu.

Claim 18. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, X³ is Asp or D-Asp, X⁴ is Gly, Ala or Ser, X⁵ is Leu, and X⁶ is Arg.

Claim 19. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, X³ is Asp or D-Asp, X⁴ is Gly, Ala or Ser, X⁵ is Leu, X⁶ is Arg, and R¹ is 1-10 amino acids selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and H₂N-(CH₂CH₂O)_m-(CH₂)_n-COOH, m and n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, and m + n is > 0.


Claim 20. (Previously Presented) A compound according to claim 1, wherein X¹ is Gly or Thr, X² is Leu, X³ is Asp or D-Asp, X⁴ is Gly, Ala or Ser, X⁵ is Leu, X⁶ is Arg, and R¹ is 1-6 amino acids selected from the group consisting of Gly, β-Ala, Abu or Aha.

Claim 21. (Withdrawn) A diagnostic agent comprising a peptide compound of claim 1 conjugated to a biological marker.

Claim 22. (Withdrawn) A diagnostic agent of claim 21, wherein said marker is biotinyl radical or a fluorescent dye radical.

Claim 23. (Withdrawn) A diagnostic agent of claim 21, wherein said marker is a GFP or an antibody.

Claim 24. (New) A peptide compound of formula I



in which

X^1 is Ser, Gly or Thr,

X^2 is Leu, Ile, Nle, Val or Phe,

X^3 is Asp, Glu, Lys or Phe,

X^4 is Gly, Ala or Ser,

X^5 is Leu, Ile, Nle, Val or Phe,


X^6 is Arg, Har or Lys,

R^1 is one or more α -aminocarboxylic acid residue(s) and/or ω -aminocarboxylic acid residue(s) having a combined length of 500 to 2500 pm

wherein

the amino acids mentioned are optionally derivatized at the NH functional group or the terminal amide functional group, the side chain carboxyl group or the $-\text{NH}-\text{C}(=\text{NH})-\text{NH}_2$ group of Arg, and the D and the L forms of the optically active amino acid residues are included.

Claim 25. (New) A peptide compound according to claim 24, of formula I



in which

X^1 is Ser, Gly or Thr,

X^2 is Leu, Ile, Nle, Val or Phe,

X^3 is Asp, Glu, Lys or Phe,

X^4 is Gly, Ala or Ser,

X^5 is Leu, Ile, Nle, Val or Phe,

X^6 is Arg, Har or Lys,

R^1 is one or more α -aminocarboxylic acid residue(s) and/or ω -aminocarboxylic acid residue(s) having a combined length of 500 to 2500 pm and is selected from the group consisting of Ala, Asn, Asp, Arg, Cys, Gln, Glu, Hcy, His, Hse, Ile, Leu, Lys, Met, Pen, Phe, Pro, Ser, Thr, Trp, Tyr, Val and

$H_2N-(CH_2CH_2O)_m-(CH_2)_n-COOH$, wherein

m, n in each case independently of one another are 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12,

with the proviso that $m + n > 0$

wherein

the amino acids mentioned are optionally derivatized at the NH functional group or the terminal amide functional group, the side chain carboxyl group or the $-NH-C(=NH)-NH_2$ group of Arg, and

the D and the L forms of the optically active amino acid residues are included.